Prostate cancer decisions — 2024

The Veteran's prostate cancer with voiding dysfunction residuals is rated at 40 percent disabling, effective September 1, 2008. The rating was decreased to 20 percent effective May 24, 2023.

The Veteran's claim for a compensable rating for residuals of prostate cancer, as residual voiding dysfunction status post prostate cancer, from June 1, 2016 is being remanded due to the failure to obtain relevant private treatment records.

The Veteran's service connection claims for diabetes mellitus, type II, erectile dysfunction, hypertension, prostate cancer, and bilateral lower extremity peripheral neuropathy are remanded due to a duty to assist error in obtaining his service records.

The Veteran's prostate cancer with voiding dysfunction residuals is rated at 40 percent disabling, effective September 1, 2008. The rating was decreased to 20 percent effective May 24, 2023.

The Veteran's prostate cancer with voiding dysfunction residuals is rated at 40 percent disabling, effective September 1, 2008. The rating was decreased to 20 percent effective May 24, 2023.

The Veteran's TDIU claim is remanded due to the need for additional evidence from SSA regarding his disability benefits.

The Veteran's claim for service connection for prostate cancer is remanded due to insufficient evidence and the need for a TERA examination. The Veteran claims exposure to Agent Blue and Agent Orange, but there are no records of his service in Korea or Thailand.

The Veteran's service connection claims for coronary artery disease, prostate cancer, and secondary service connection for erectile dysfunction are all granted due to exposure to herbicide agents during his service in Thailand.

The Board has granted the Veteran's appeals for service connection for prostate cancer, hypertension, and thyroid disability. The appeal was based on evidence showing these conditions were due to exposure to toxins and chemicals during his military service.

The Board has remanded the case due to incomplete opinions and the need for additional exposure information, including asbestos exposure. The Veteran's prostate cancer claim is being reconsidered with consideration of all toxic exposures.

The Board denied service connection for prostate cancer and ischemic heart disease (IHD) as there was no evidence of herbicide exposure in service, and the claims were not supported by other theories of service connection.

The Board has granted service connection for prostate cancer and erectile dysfunction as secondary to prostate cancer, finding that the Veteran's conditions are related to his active duty service due to herbicide exposure.

The Board has remanded the claims of service connection for prostate cancer and erectile dysfunction, as well as SMC based on loss of use due to a duty to assist error. A VA examination is required to determine the nature and etiology of the Veteran's diagnosed conditions.

The Veteran's claims for service connection for prostate cancer and coronary artery disease were granted effective January 20, 2022. An initial rating of 40 percent was assigned for prostate cancer residuals.

The Veteran's prostate cancer is granted effective August 10, 2022, due to the PACT Act presumption of service connection for burn pit exposure.

The Veteran's appeal for a total disability rating based on individual unemployability (TDIU) due to service-connected disabilities was denied. The evidence did not substantiate a reasonable possibility that the Veteran is unable to secure or follow a substantially gainful occupation.

The Board has remanded the claims for service connection for prostate cancer, bilateral deep vein thrombosis, and gastroesophageal reflux disease due to a duty to assist error in failing to consider the Veteran's exposure to contaminated water at Camp Lejeune. The claims are being returned to the AOJ for further action.

The Veteran's service-connected disabilities render him so incapable of performing the activities of daily living that he requires care or assistance on a regular basis to protect him from hazards or dangers incident to his daily environment. The Board has granted SMC based on the need for aid and attendance.

The Veteran's prostate cancer rating was reduced from 100% to 40%, but the restoration of the 100% rating is denied. A higher rating (60%) for his residuals, including use of an appliance such as a catheter, is granted.

The Veteran's claims for an initial compensable rating for bilateral hearing loss and service connection for prostate cancer are being remanded due to the need to consider additional evidence, including audiogram results from CPRS and medical records related to his prostate cancer treatment. The Board also notes that VA did not obtain a VA examination or medical opinion regarding the etiology of the Veteran's prostate cancer.